相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice
Aaron P. Mitchell et al.
ONCOLOGIST (2020)
Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma
Arjun Gupta et al.
JAMA ONCOLOGY (2020)
Assessment of Parking Fees at National Cancer Institute-Designated Cancer Treatment Centers
Anna Lee et al.
JAMA ONCOLOGY (2020)
Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study
Yeon-Hee Baek et al.
CANCER EPIDEMIOLOGY (2019)
Economic Burden Associated with Cancer Caregiving
Cathy J. Bradley
SEMINARS IN ONCOLOGY NURSING (2019)
Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review
Aaron P. Mitchell et al.
JAMA ONCOLOGY (2019)
Practice Patterns for Older Adult Patients With Advanced Cancer: Physician Office Versus Hospital Outpatient Setting
Allison Lipitz-Snyderman et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics
Aaron Mitchell et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen et al.
EUROPEAN UROLOGY (2018)
Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw
Tomoko Higuchi et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2018)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
L. E. Howard et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians
Karen A. Autio et al.
CLINICAL GENITOURINARY CANCER (2015)
Using claims data to predict dependency in activities of daily living as a proxy for frailty
Keturah R. Faurot et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2015)
Burden of skeletal-related events in prostate cancer: unmet need in pain improvement
M. S. Broder et al.
SUPPORTIVE CARE IN CANCER (2015)
The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine
Nicole C. Wright et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 ( Alliance)
Matthew R. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Payment for Oncolytics in the United States: A History of Buy and Bill and Proposals for Reform
Blase N. Polite et al.
JOURNAL OF ONCOLOGY PRACTICE (2014)
Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems
Gerry Oster et al.
SUPPORTIVE CARE IN CANCER (2013)
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
F. Saad et al.
ANNALS OF ONCOLOGY (2012)
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton et al.
EUROPEAN JOURNAL OF CANCER (2012)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis
Sonya J. Snedecor et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
The potential impact of new National Osteoporosis Foundation guidance on treatment patterns
B. Dawson-Hughes et al.
OSTEOPOROSIS INTERNATIONAL (2010)
FRAX (R) and its applications to clinical practice
John A. Kanis et al.
BONE (2009)
Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
SD Reed et al.
JOURNAL OF UROLOGY (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The new bisphosphonate, Zometa((R)) (Zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate
A Lipton et al.
CANCER INVESTIGATION (2002)
Development of a comorbidity index using physician claims data
CN Klabunde et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
分享论文
